ASLAN Pharmaceuticals’ $42 Million Initial Public Offering

Cooley advised ASLAN Pharmaceuticals Limited on its $42 million initial public offering of 6,000,000 American Depositary Shares, each representing five ordinary shares.

Leerink Partners and Piper Jaffray acted as joint book-running managers for the offering. BTIG, H.C. Wainwright & Co. and CLSA acted as co-managers for the offering.

This IPO marks the first Taipei Exchange-listed company to go public in the US. The ADSs now trade on the Nasdaq Global Market under the symbol “ASLN” and the ordinary shares have traded on the Tapei Exchange since Q2 2017 under the symbol “6497.”

ASLAN is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. Aslan targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. The company, led by Carl Firth, William Jeffrey Tomlinson and Mark McHale is based in Singapore.

Cooley advised ASLAN with a team led by Patrick Loofbourrow (Picture), Charlie Kim, Rob Phillips, Sean Clayton and Dave Peinsipp.

Involved fees earner: Patrick Loofbourrow – Cooley LLP; Charlie Kim – Cooley LLP; Robert Phillips – Cooley LLP; Sean Clayton – Cooley LLP; David Peinsipp – Cooley LLP; Kristin VanderPas – Cooley LLP; Carlos Ramirez – Cooley LLP; Adrienne Directo – Cooley LLP; Andrew Cates – Cooley LLP; Bin Wang – Cooley LLP; Phillip McGill – Cooley LLP; Micah Youngdale – Cooley LLP; Daniel Goldberger – Cooley LLP; Francis Wheeler – Cooley LLP; Barbara Mirza – Cooley LLP; Natasha Leskovsek – Cooley LLP; Phil Mitchell – Cooley LLP; Susan Cooper Philpot – Cooley LLP; Mark Windfeld-Hansen – Cooley LLP;

Law Firms: Cooley LLP;

Clients: ASLAN Pharmaceuticals Ltd;


Author: Michael Patrini